Houston, TX and Chicago, IL – January 8, 2025: CTMC, a joint venture between MD Anderson Cancer Center and Resilience, has entered a partnership with Syenex to advance the scalability and efficiency of engineered T cell therapies. Through this collaboration, CTMC will gain access to Syenex’s bioengineering systems, which provide a significant improvement in gene delivery efficiency and engineering timelines.
Download the full article: FINAL_Syenex_CTMC-PR_01.08.2025.pdf